Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCT-547
- Development stage
- Preclinical
- Lead developer
- Korea University Guro Hospital
01
Overview
NCT-547: sourced facts only. name: "A novel C-terminal of HSP90 inhibitor NCT-547 eliminates cancer stem-like subpopulation in triple-negative breast cancer" [DOI:10.1158/1538-7445.am2023-4911]; target: "A novel C-terminal of HSP90 inhibitor NCT-547 eliminates cancer stem-like subpopulation in triple-negative breast cancer" [DOI:10.1158/1538-7445.am2023-4911]; developer: "1Korea University Guro Hospital, Seoul, Republic of Korea." [DOI:10.1158/1538-7445.am2023-4911]; stage: "NCT-547 effectively targets both the proliferating TNBC tumor cells and CSCs, markedly reducing tumor growth, coinciding with decreased Ki-67 proliferation index and enhanced apoptosis." [DOI:10.1158/1538-7445.am2023-4911]
02
Targets
HSP90AA1 (Heat shock protein HSP90-alpha)
Beyond the preview
Go deeper on NCT-547.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NCT-547.